HeartSciences (HSCS) EBITDA Margin (2021 - 2025)

HeartSciences has reported EBITDA Margin for 5 years, with the latest figure at 85713.23% in Q4 2025.

• For the quarter ending Q4 2025, EBITDA Margin changed N/A year-over-year to 85713.23%; the trailing twelve-month figure through Jan 2026 stood at 89939.57% (down 4525160.0% YoY), and the FY2025 full-year result was 192013.13%, down 15811114.0% from the prior year.
• EBITDA Margin for Q4 2025 stood at 85713.23%, up from 98637.84% in the prior quarter.
• The five-year high for EBITDA Margin was 9011.84% in Q3 2021, with the low at 98637.84% in Q3 2025.
• Historically, EBITDA Margin has averaged 48780.2% across 5 years, with a median of 44418.82% in 2025.
• Annual changes were most pronounced in 2022 — EBITDA Margin tumbled 3567869 bps — and 2024, when it surged 5676700 bps.
• HeartSciences' EBITDA Margin stood at 9011.84% in 2021, then sank by 396 bps to 44690.53% in 2022, then increased by 10 bps to 40254.95% in 2023, then soared by 74 bps to 10376.75% in 2024, then slumped by 726 bps to 85713.23% in 2025.
• The last three EBITDA Margin figures came in at 85713.23% (Q4 2025), 98637.84% (Q3 2025), and 44147.1% (Q2 2025), per Business Quant data.